Connect MM Registry as a national reference for United States multiple myeloma patients

Abstract

Background: The Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB) show improved overall survival (OS) in patients with multiple myeloma (MM) over the last 15 years. This analysis evaluated the validity of the largely community-based Connect MM Registry as a national reference for MM.

Methods: Baseline disease characteristics and survival in US newly diagnosed MM patients were examined using the Connect MM Registry as well as SEER and NCDB databases. Baseline characteristics predictive of longer survival in Connect MM were also identified.

Results: As of February 2017, 3011 patients were enrolled in the Connect MM Registry; 2912 were treated. Median age at time of MM diagnosis and age range were numerically similar from 2010 to 2015 across all 3 registries; SEER had a higher representation of nonwhite racial groups than that in the other 2 registries. OS rates suggest proportionate improvement with year of diagnosis among the 3 registries. A Cox proportional hazards model suggests that younger age (<65 years) is associated with longer survival (vs ≥75; HR, 0.39; 95% confidence interval, 0.34-0.46) in the Connect MM Registry. However, sex (HR, 0.91; P = .15) and race (black vs white; HR, 0.88; P = .21) were not associated with longer OS.

Conclusions: Data from the Connect MM Registry appear to be largely representative of national trends, comprehensive, and reliable representations of the national MM population. Baseline characteristics were comparable, and survival similarly improved over time among the 3 registries. CLINICALTRIALS.

Gov, identifier: NCT01081028.

Keywords: multiple myeloma; registries; survival.

Conflict of interest statement

Sikander Ailawadhi provided consultancy services to Takeda, Novartis, Celgene, and Amgen; he received research funding from Pharmacyclics. Sundar Jagannath provided consultancy services to Celgene, Bristol‐Myers Squibb, Novartis, and Merck; he participated in speakers’ bureaus for MMRF and Medicom. Mohit Narang provided consultancy services and participated in speakers’ bureaus for Celgene; he participated in speakers’ bureaus for Janssen. Robert M. Rifkin provided consultancy services to Amgen, Boehringer Ingelheim, Celgene, EMD Serono, Sandoz, and Takeda; he owns stock with McKesson. Howard R. Terebelo provided consultancy services to Celgene; he participated in speakers’ bureaus for Janssen, Takeda, and Pharmacyclics LLC, an AbbVie Company. Kathleen Toomey provided consultancy services to Celgene, participated in speakers’ bureaus for Myriad Genetics, and received travel reimbursement from Dava Oncology. Brian GM Durie provided consultancy services to Takeda and Janssen. James W. Hardin provided consultancy services to Celgene. Cristina J. Gasparetto received honoraria from Janssen, Bristol‐Myers Squibb, Celgene, and Takeda, provided consultancy services to Janssen, Bristol‐Myers Squibb, and Celgene; she received travel reimbursement from Janssen, Bristol‐Myers Squibb, and Celgene, and received research funding from Celgene. Lynne Wagner provided consultancy services to EveryFit, Gilead, and Janssen. James L. Omel received honoraria from Takeda Oncology and Celgene; he is on the board of directors/advisory committee for Takeda Oncology and Celgene. Vivek Kumar has no conflicts of interest to disclose. Lihua Yue, Amani Kitali, and Amit Agarwal are employed by Celgene. Rafat Abonour is a member of steering committees for Celgene and Takeda, has received research funding from Celgene and Takeda, and has received research funding from Prothena.

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1

A, Connect MM, SEER‐9, and NCDB sites. B, Connect MM OS by year of enrollment. 2009 and 2010 data were combined. OS was adjusted for the following covariates: age group, sex, and race. MM indicates multiple myeloma; NCDB, National Cancer Database; OS, overall survival; SEER, Surveillance, Epidemiology, and End Results; US, United States.